Goldman Sachs Group Inc Bio Atla, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.37 - $3.92 $427,078 - $1.22 Million	311,736 Added 660.68%	358,920 $491,000
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $15,854 - $29,178	8,433 Added 21.76%	47,184 $162,000
Q4 2023 Feb 13, 2024	SELL	$1.27 - $3.18 $13,185 - $33,014	-10,382 Reduced 21.13%	38,751 $95,000
Q3 2023 May 14, 2024	BUY	$1.7 - $3.07 $17,649 - $31,872	10,382 Added 26.79%	49,133 $83,000
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $56,246 - $101,574	-33,086 Reduced 40.24%	49,133 $83,000
Q2 2023 May 14, 2024	BUY	$2.83 - $3.87 $72,108 - $98,607	25,480 Added 44.91%	82,219 $246,000
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $72,108 - $98,607	25,480 Added 44.91%	82,219 $246,000
Q1 2023 May 14, 2024	SELL	$2.3 - $8.25 $83,515 - $299,565	-36,311 Reduced 39.02%	56,739 $152,000
Q1 2023 May 11, 2023	SELL	$2.3 - $8.25 $83,515 - $299,565	-36,311 Reduced 39.02%	56,739 $152,000
Q4 2022 May 14, 2024	SELL	$6.29 - $11.01 $77,027 - $134,828	-12,246 Reduced 11.63%	93,050 $767,000
Q4 2022 Feb 13, 2023	SELL	$6.29 - $11.01 $77,027 - $134,828	-12,246 Reduced 11.63%	93,050 $767,000
Q3 2022 May 14, 2024	BUY	$2.94 - $11.87 $82,225 - $331,980	27,968 Added 36.17%	105,296 $811,000
Q3 2022 Nov 10, 2022	BUY	$2.94 - $11.87 $82,225 - $331,980	27,968 Added 36.17%	105,296 $0
Q2 2022 May 14, 2024	BUY	$2.13 - $5.38 $82,169 - $207,544	38,577 Added 99.55%	77,328 $220,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $230,223 - $581,502	-108,086 Reduced 58.29%	77,328 $220,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $579,189 - $2.48 Million	132,235 Added 248.66%	185,414 $927,000
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $122,930 - $200,246	6,470 Added 13.85%	53,179 $1.04 Million
Q3 2021 Nov 10, 2021	BUY	$29.44 - $43.74 $1.38 Million - $2.04 Million	46,709 New	46,709 $1.38 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.3M

Call Options Held

500

Put Options Held

33.5K

Israel Englander Millennium Management LLC | New York, Ny

2.66M
Shares

$4.57 Million
0.0% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

2.52M
Shares

$4.33 Million
0.38% of portfolio
Vanguard Group Inc Valley Forge, PA

1.89M
Shares

$3.24 Million
0.0% of portfolio
Morgan Stanley New York, NY

1.86M
Shares

$3.2 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

874K
Shares

$1.5 Million
0.13% of portfolio

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account